Document is current

Article History

Received: 11 August 2020

Accepted: 23 September 2020

First Online: 30 September 2020

Compliance with ethical standards

:

: Boris Böll received grants from Astra Zeneca and Sanofi; personal fees from Celgene, MSD, Roche, and Takeda; and personal fees from Baxalta, Mundipharma, and J&J outside the submitted work.Dieter Buchheidt received research grants from Gilead Sciences and Pfizer; served on the speakers’ bureau of Gilead Sciences, Merck Sharp & Dohme/Merck, and Pfizer; and received travel grants from Gilead Sciences, Merck Sharp & Dohme/Merck, and Pfizer, outside the submitted work.Justin Hasenkamp received honoraria as a consultant from AMGEN, Bristol-Myers Squibb, Celgene, Gilead Science, Jazz Pharmaceuticals, MSD Sharp & Dohme, Neovii, Novartis Pharma, and Mundipharma and payment for educational presentations (written or oral) from Deutscher Ärzte-Verlag, Georg Thieme Verlag, MedKom Akademie, and NewConceptOncology GmbH outside the submitted work.Michael Koldehoff received lecture honoraria from CSL Behring and AURIKAMED outside the submitted work.Olaf Penack has received honoraria and travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, and Pfizer. He has received research support from Bio Rad, Gilead, Incyte, Jazz, Neovii Biotech, Pierre Fabre, Sanofi, and Takeda. He is a member of the advisory board to Jazz, Gilead, MSD, Omeros, and SOBI.Markus Ruhnke was a consultant to Basilea, Daiichi Sankyo, Kedplasma, Janssen, and Scynexis and received payment for development of educational presentations from Basilea and Janssen.Matthias Kochanek received lecture honoraria from Astellas, Gilead, MSD, and Pfizer outside the submitted work.Sibylle C. Mellinghoff was a consultant to Octapharma. She has received research funding by the DMyKG, the German Centre for Infection Research, and the University Hospital of Cologne.All other authors declare no potential competing interests.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.